Dehui Zou, Dr.
Institute of Hematology & Blood Diseases Hospital, China
6
6
2
N/A
0
5
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+8 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (6)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Weili Zhao, Dr.
Ruijin Hospital
Shared therapeutic areas:
Worked with same sponsors:
Mitchell Cairo, MD
New York Medical College
Shared therapeutic areas:
Helen Heslop, MD
Baylor College of Medicine
Shared therapeutic areas:
Roberto Hernández Martín, MD
Hospital Virgen de la Concha
Shared therapeutic areas:
Elena Pérez Ceballos, MD
Hospital Morales Meseguer
Shared therapeutic areas:
Qifa Liu
Nanfang Hospital, Southern Medical University
Shared therapeutic areas:
Worked with same sponsors:
Carlos Montalbán Sanz, MD
Hospital Universitario Ramon y Cajal
Shared therapeutic areas:
Eulogio Conde García, MD
Hospital Marqués de Valdecilla
Shared therapeutic areas:
Mary Horowitz, MD
Center for International Blood and Marrow Transplant Research
Shared therapeutic areas:
Arnon Nagler, MD
Chaim Sheba Medical Center
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (6)
Showing 6 of 6 trials
Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma
All 6 trials loaded